952665-30-4

Basic information

• Product Name: 2-tert-butyl-4-methylphenyl diethyl phosphate
• Synonyms: 2-tert-butyl-4-methylphenyl diethyl phosphate
• CAS NO: 952665-30-4
• Molecular Weight: 300.335
• Mol File: 952665-30-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-tert-butyl-4-methylphenyl diethyl phosphate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-tert-butyl-4-methylphenyl diethyl phosphate(952665-30-4)
• EPA Substance Registry System: 2-tert-butyl-4-methylphenyl diethyl phosphate(952665-30-4)

Safety Data

• Hazardous Substances Data: 952665-30-4(Hazardous Substances Data)

Upstream product

• 2409-55-4 2-tert-Butyl-4-methylphenol 
• 814-49-3 diethyl chlorophosphate 

Downstream Products

• 873055-31-3 5-(tert-butyl)-1H-indol-6-amine 
• 99758-45-9 1-(tert-butyl)-5-methyl-2,4-dinitrobenzene 
• 107342-39-2 1-(tert-butyl)-3-methyl-2,4-dinitrobenzene 
• 952665-31-5 (E)-2-(5-(tert-butyl)-2,4-dinitrophenyl)-N,N-dimethylethenamine 
• 1075-38-3 m-t-butyltoluene 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.